patients

Sight Sciences Launches Ergo-Series of OMNI Surgical System in US

Source Node: https://zephyrnet.com/sight-sciences-introduces-ergo-series-of-omni-surgical-system-in-us/
Time Stamp: March 10, 2023 11:57 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Sight Sciences, a leading provider of ophthalmic solutions, has recently announced the launch of their Ergo-Series of OMNI Surgical System in the United States. This new system is designed to improve the safety and efficiency of cataract surgery, while providing surgeons with greater control over the procedure.The Ergo-Series of OMNI Surgical System is a fully automated system that uses advanced technology to provide surgeons with greater control over the procedure. It features a unique ergonomic design that allows for improved access to the eye and better visibility during the procedure.

Sight Sciences Launches Ergo-Series of OMNI Surgical System in the US

Source Node: https://zephyrnet.com/sight-sciences-introduces-ergo-series-of-omni-surgical-system-in-us/
Time Stamp: March 10, 2023 11:57 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Sight Sciences, a leading provider of ophthalmology solutions, has recently announced the launch of its Ergo-Series of OMNI Surgical System in the United States. The OMNI Surgical System is a revolutionary new platform that provides surgeons with unprecedented control and precision during ophthalmic surgery.The Ergo-Series of OMNI Surgical System is designed to provide surgeons with greater control and accuracy during ophthalmic surgery. The system features a unique ergonomic design that allows surgeons to easily adjust the angle of the surgical instrument to best suit the patient’s anatomy. This allows for

Lipid Nanoparticles Demonstrate High Efficiency in Gene Therapy

Source Node: https://zephyrnet.com/lipid-nanoparticles-highly-effective-in-gene-therapy/
Time Stamp: March 10, 2023 11:24 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Gene therapy is a rapidly growing field of medical research that has the potential to revolutionize the way we treat a variety of diseases. One of the most promising developments in this field is the use of lipid nanoparticles (LNPs) to deliver therapeutic genes to cells. LNPs are small particles made up of lipids, or fats, and are capable of carrying genetic material into cells. Recent studies have demonstrated that LNPs are highly efficient at delivering genes to cells, making them a promising tool for gene therapy.The first step in

A Comprehensive Overview of 3D Printing in Medical Device Manufacturing

Source Node: https://zephyrnet.com/complete-guide-for-3d-printing-in-medical-device-manufacturing/
Time Stamp: March 10, 2023 10:22 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

The use of 3D printing in medical device manufacturing is revolutionizing the healthcare industry. 3D printing, also known as additive manufacturing, is a process of creating three-dimensional objects from a digital file. This technology has been used to create medical devices such as prosthetics, implants, and surgical tools. In recent years, 3D printing has become increasingly popular in the medical device manufacturing industry due to its ability to create complex and customized parts quickly and cost-effectively.The first step in 3D printing for medical device manufacturing is the creation of a

Qiagen and Servier Collaborate to Create Diagnostic Test for Acute Myeloid Leukemia Treatment

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Qiagen, a global leader in molecular diagnostics, and Servier, a global pharmaceutical company, have recently announced a collaboration to create a diagnostic test for acute myeloid leukemia (AML) treatment. The test will be used to identify patients who are likely to respond to specific treatments for AML.AML is a type of cancer that affects the bone marrow and blood cells. It is the most common type of leukemia in adults, and it is often difficult to treat. The current standard of care for AML is chemotherapy, but many patients do

Qiagen and Servier Collaborate to Create Diagnostic Tool for Acute Myeloid Leukemia Treatment

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Qiagen and Servier, two leading biopharmaceutical companies, have recently announced a collaboration to develop a diagnostic tool for acute myeloid leukemia (AML) treatment. This new tool will provide physicians with the ability to accurately diagnose and treat AML patients more effectively.Acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. It is a fast-growing form of cancer that can be difficult to diagnose and treat. Currently, the diagnosis of AML is based on the patient's symptoms and laboratory tests. However, this method is not always

Qiagen and Servier Collaborate to Create Diagnostic Test for Acute Myeloid Leukemia.

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Qiagen and Servier have recently announced a collaboration to create a diagnostic test for acute myeloid leukemia (AML). This test will be used to identify patients with AML and to determine the best course of treatment for them. The test is expected to be available in Europe in 2021. Acute myeloid leukemia is a type of cancer that affects the bone marrow and blood cells. It is a serious and life-threatening condition that can cause a range of symptoms, including fatigue, fever, weight loss, and anemia. It is estimated that

Qiagen and Servier Collaborate to Develop Novel Diagnostic Test for Acute Myeloid Leukemia

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Acute myeloid leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is an aggressive form of cancer that can be difficult to diagnose and treat. Recently, two major companies, Qiagen and Servier, have announced a collaboration to develop a novel diagnostic test for AML.Qiagen is a global leader in molecular diagnostics and sample technologies. They specialize in developing tests that can detect and diagnose a variety of diseases. Servier is a French pharmaceutical company that focuses on developing treatments for cancer and other diseases.

Qiagen and Servier Collaborate to Create New Test for Acute Myeloid Leukemia Drug

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Qiagen and Servier have recently announced a collaboration to create a new test for Acute Myeloid Leukemia (AML) drug. The test will be used to identify patients who are likely to respond to a specific type of AML drug called midostaurin. This new test will be based on the use of Qiagen's proprietary technology, which is designed to detect genetic biomarkers in the blood of patients with AML.The test will be used to identify patients who are likely to respond to midostaurin, an AML drug developed by Servier. Midostaurin is

Qiagen and Servier Collaborate on Development of Test for Acute Myeloid Leukemia Drug

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Qiagen and Servier have recently announced a collaboration to develop a test for acute myeloid leukemia (AML) drug. The test will use Qiagen's proprietary technology to detect the presence of a specific biomarker in blood samples that can be used to identify patients who may benefit from treatment with Servier's drug, Rydapt.The test will be based on Qiagen's QuantiGene Plex technology, which is a multiplexed gene expression assay. This technology uses a single sample of blood to measure the expression of multiple genes associated with AML. By detecting the presence

Qiagen and Servier Collaborate to Develop Diagnostic Test for Acute Myeloid Leukemia Treatment

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Qiagen and Servier have announced a new collaboration to develop a diagnostic test for acute myeloid leukemia (AML) treatment. The partnership will leverage Qiagen's expertise in molecular diagnostics and Servier's experience in drug development to create a test that can accurately detect and monitor AML. AML is a type of cancer that affects the bone marrow and blood. It is an aggressive form of cancer that can be difficult to treat. Currently, diagnosis and treatment of AML relies on a variety of tests, including bone marrow biopsies, blood tests, and

Qiagen and Servier Collaborate to Create Test for Acute Myeloid Leukemia Drug

Source Node: https://zephyrnet.com/qiagen-partners-with-servier-to-develop-new-test-for-aml-drug/
Time Stamp: March 10, 2023 10:04 AM - Modified On: March 10, 2023 - Published By:
Source Cluster:
Published by Plato

Qiagen and Servier, two leading pharmaceutical companies, have recently announced a collaboration to create a new test for acute myeloid leukemia (AML). The test will be used to identify patients who are likely to respond to a new drug developed by Servier, called midostaurin. This drug is currently in clinical trials and has shown promising results in treating AML. AML is an aggressive form of blood cancer that affects the bone marrow and is characterized by the rapid growth of abnormal white blood cells. It is the most common type